If MIGS does indeed become standard of care for glaucoma (which is what appears to be happening, especially in the USA) then this should easily be a multi-billion dollar stock based on iTrack Advance alone. Glaukos is already there with a US$4 billion (AU$6 billion) market cap. It's pretty clear that doctors are shifting from stents and towards canaloplasty, so we should expect to take significant market share from them especially now with the new device.
Add a few new treatments to the mix (Nova Eye has indicated that they are working on new devices), and 2RT, the sky's the limit here
If MIGS does indeed become standard of care for glaucoma (which...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $56.06M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.5¢ | 22.5¢ | $166.2K | 700.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 7999 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
24.5¢ |
Change
0.005 ( 2.08 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 25.0¢ | 22.5¢ | 370408 | ||
| Last updated 15.58pm 31/05/2024 ? | |||||
| EYE (ASX) Chart |